Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CBER’s ‘Courageous’ Coronavirus Guidance Strategy May Catch-On

Executive Summary

Director Peter Marks says faster guidance development practices produced well-written documents and may be adopted once the pandemic ends.

You may also be interested in...



Elizabeth Jungman: Interpreter Of The FDA’s Policy Crystal Ball

The Center for Drug Evaluation and Research’s policy guru must think about the future, along with the present, in her position as director of the Office of Regulatory Policy.

US FDA CDER, CBER Staff Say Pandemic Had Negative Effect On Hiring, Retention

Human resource managers also worried that since universal teleworking was valued by employees, a return to pre-pandemic conditions could cause a mass exodus.

Priority And Standard Review Times Increasingly Similar As Application Totals Diverge

Standard NMEs and BLAs decrease along with their review times, as more sponsors use priority pathway.

Related Content

Topics

UsernamePublicRestriction

Register

PS142445

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel